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Introduction: Pancreatic adenocarcinoma (PAC) has some of the worst treatment
outcomes for any solid tumor. PAC creates substantial difficulty for effective treatment
with traditional RT delivery strategies primarily secondary to its location and limited
visualization using CT. Several of these challenges are uniquely addressed with MR-
guided RT. We sought to summarize and place into context the currently available
literature on MR-guided RT specifically for PAC.
Methods: A literature search was conducted to identify manuscript publications since
September 2014 that specifically used MR-guided RT for the treatment of PAC. Clinical
outcomes of these series are summarized, discussed, and placed into the context of the
existing pancreatic literature. Multiple international experts were involved to optimally
contextualize these publications.
Results: Over 300 manuscripts were reviewed. A total of 6 clinical outcomes publications
were identified that have treated patients with PAC using MR guidance. Successes,
challenges, and future directions for this technology are evident in these publications. MR-
guided RT holds theoretical promise for the treatment of patients with PAC. As with any
new technology, immediate or dramatic clinical improvements associated with its use will
take time and experience. There remain no prospective trials, currently publications are
limited to small retrospective experiences. The current level of evidence for MR guidance
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in PAC is low and requires significant expansion. Future directions and ongoing studies that
are currently open and accruing are identified and reviewed.
Conclusions: The potential promise of MR-guided RT for PAC is highlighted, the challenges
associated with this novel therapeutic intervention are also reviewed. Outcomes are very early,
and will require continued and long term follow up. MR-guided RT should not be viewed in the
same fashion as a novel chemotherapeutic agent for which dosing, administration, and toxicity
has been established in earlier phase studies. Instead, it should be viewed as a novel
procedural intervention which must be robustly tested, refined and practiced before
definitive conclusions on the potential benefits or detriments can be determined. The future
of MR-guided RT for PAC is highly promising and the potential implications on PAC
are substantial.
Keywords: MRI guidance, pancreatic image–guided RT, pancreatic cancer and radiation therapy, pancreatic cancer,
MR-guided RT, MR-guided radiation therapy
INTRODUCTION
Pancreatic adenocarcinoma (PAC) has some of the worst
treatment outcomes for any solid tumor (1). Median overall
survival (OS) remains absolutely dismal for the vast majority of
patients afflicted with PAC. It has risen to the fourth leading
cause of cancer death in the United States (US), approaching
colon and rectal cancer (1). In the next fifteen years, the projected
impact of PAC is expected to increase, placing it as one of the top
three causes of cancer death by 2030 (2). Radiation therapy (RT)
remains controversial in PAC (3). On the one hand, RT is a
highly compelling treatment strategy for PAC. Currently RT is
successfully applied as a single modality, or in combination with
systemic therapy, in curative treatment strategies in most
adenocarcinomas and other tumors (4). On the other hand, RT
in PAC is challenging due to the proximity of various
radiosensitive normal structures like the duodenum, bowel and
stomach. Deposition of curative RT doses while sparing the
adjacent normal tissues is challenging with conventional RT
techniques as the tumor and surrounding structures are highly
mobile and difficult to see on CT based imaging. For a long
time these limitations have hampered the use of curative
RT doses on PAC causing somewhat modest treatment results
when using RT in PAC. Recently MR-guided RT has emerged
as a potential strategy to improve the therapeutic index of RT
(5–8). For a variety of reasons, the MR-guided method seems
optimally suited for the treatment of PAC. We sought to
summarize and place into context the currently available
literature on MR-guided RT for PAC. We highlight the
potential promise, but also the challenges associated with this
novel therapeutic intervention.
METHODS AND LITERATURE REVIEWED
A literature search was conducted using PubMed and Google
Scholar to identify manuscript publications since September
2014 that specifically used MR-guided RT for the treatment of
PAC. The goal of this search was to include manuscripts that
describe the treatment of patients using FDA approved MR-
guided RT technology. Search terms included: MR guided
radiation and pancreatic cancer, MRI and RT and pancreatic
cancer, image guided radiation therapy and pancreatic cancer,
IGRT and pancreatic cancer. Over 300 search results were
individually reviewed and multiple “similar article” links were
subsequently referenced and also reviewed. Articles that merely
incorporated MRI in the treatment planning process were
excluded. Articles considered to be case reports (fewer than 3
patients) were excluded. Articles devoted purely to dosimetric
feasibility were also excluded. Clinical outcomes of these series
are summarized, discussed, and placed into context of existing
pancreatic literature. Attention was given to dose constraints,
which are summarized in Table 1.
DISCUSSION
MR-guided RT holds theoretical promise for the treatment of
patients with PAC. As with any new technology, immediate or
dramatic clinical improvements associated with its use will likely
take time and experience. MR-guided RT should not be viewed
in the same fashion as a novel chemotherapeutic agent for which
dosing, administration, and toxicity has been established in
earlier phase studies. Instead, it should be viewed as a novel
procedural intervention which must be robustly tested, refined
and practiced before definitive conclusions on the potential
benefits or detriments can be determined (15).
Controversies in the Use of RT for PAC
There are several reasons for the seemingly intangible capacity of
RT to present itself as a durable and consistently curative
modality for PAC. First, and perhaps most relevant, is the high
propensity for PAC to metastasize. When the majority of
patients develop distant metastatic disease, the ability for a
local modality, such as surgery or RT, to demonstrate
meaningful improvements in OS, is difficult. Proof of the
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benefit of RT could be accomplished, but it would require
comparative trials of large numbers of patients who survive
long enough to demonstrate the benefit of durable local
control. Given that the majority of patients with PAC will die
of distant metastatic disease progression such trials are difficult
and have not been conducted. Regardless of how optimally local
control is achieved, this will have been pursued in vain if a
patient dies of distant metastatic disease. Despite this, distant
metastatic disease is not realized in all patients with PAC, as one
third of patients with PAC will die of predominately local disease
progression (16). As systemic therapy has become more effective
with both cytotoxic approaches and precision medicine
strategies, this percentage will likely increase (17, 18).
Maximizing local therapy will therefore become increasingly
important for patients with PAC and will potentially lead to
better OS in an era of more effective systemic therapies. Local









10 40 Gy in 5, max doses up to 50 Gy in 5, tumor + 5 mm margin Duodenum, Stomach, Small
Bowel:
V33Gy < 1 cm3
V25Gy < 20 cm3
• Clinicians can review and
adjust contours within 3 cm from
the PTV, both feasible and safe





5/20 50 Gy in 5, goal of 95% coverage by 95% prescription dose,
tumor + 5 mm margin
Stomach Max: V33 ≤ 0.5 cm3
Duodenum Max: V35 ≤ 0.5
cm3
Small Bowel Max: V30 ≤ 0.5
cm3
Large Bowel Max: V35 ≤ 0.5
cm3
• SMART is clinically deliverable
and safe




44 40-55 Gy in 25-28 fractions (n=13)
30-35 Gy in 5 fractions (n=6)
40-52 Gy in 5 fractions (n=16)




• High dose (BED10 > 70) had
improved 2 year overall survival,
49% versus 30%, p = 0.03
• Freedom from local failure was
77% in the high dose versus
57% in the standard dose
• Grade 3 GI toxicity in 3/44




35 35-50 Gy in 5 fractions, gross nodes also treated. 120%-130%
dosimetric hot spots were included, provided OAR constraints
met. 20 patients treated with ENI to celiac, SMA, and SMV to
same dose as tumor
Duodenum, Stomach, Small
Bowel:
V35 Gy < 0.5 cm3
V40 Gy < 0.03 cm3
Large Bowel:
V38 < 0.5 cm3
V43 < 0.03 cm3
• Median treatment time 83 min
(56–108)
• Five patients underwent
surgery, 1 CR, 2 NCR
• 1 year local control was 87.8%
• Median time to local
progression 7.4 months
• 1 year DMFS was 63.1%
• 1 year PFS/median PFS
52.4%/7.9 months
• Median OS was 9.8 months
(from completion of RT)
• Acute grade 3 toxicity 2.9%,
Late grade 3 toxicity 2.9%
(12)
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3/10 Mostly recurrent PAC, previously treated with RT, patients were
given 25-35 Gy in 5 fractions
Stomach: Max dose of 34 Gy
to 0.03 cm3
Duodenum: Max point dose of
34 Gy to 0.03 cm3, 33 Gy < 1
cm3, ideal-V20 < 20 cm3,
V26.5 < 5 cm3
Small Bowel: Max point dose
of 34 Gy to 0.03 cm3, ideal-
V20 < 20 cm3, V26.5 < 5 cm3
Colon: Max dose less than 34
Gy to 0.03 cm3.
• Feasibility was demonstrated
for this cohort using 1.5 Tesla
MR Linac
• Quantitative MRI can be
acquired during treatment
without longer table times
• Longer term follow up needed
for clinical outcomes such as late




44 50 Gy in 5 fractions, goal of 95% coverage by 95% prescription
dose
Esophagus, Duodenum, Small
Bowel, Stomach Large Bowel:
V36<0.75 cm3 for MR Linac
0.5 cm3
• Late grade 3 GI toxicity was
4.6%
• Median OS was 15.7 months
• One year local control was
84.3%
(14)
PAC, pancreatic adenocarcinoma; n, number of pancreatic cases included; CR, complete response; NCR, near complete response; DMFS, distant metastases free survival; PFS,
progression free survival; NR, not reported; SMA, superior mesenteric artery; SMV, superior mesenteric vein; OAR, organs at risk; GI, gastrointestinal.
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progression causes morbidity, which is difficult to treat. Effective
local therapies can reduce symptoms and improve quality of life,
both of which RT has been consistently shown to effectively
accomplish (19, 20).
RT Challenges in PAC
PAC creates a trifecta of difficulty for effective treatment with
traditional RT delivery strategies. First, is the significant difficulty
of visualizing pancreatic tumors using traditional CT-based
imaging strategies (21). The boundaries and locations of these
tumors are exceptionally difficult to distinguish (18). Pancreas
cancers are difficult to define on CT as they are hypo-attenuating
with ill-defined borders. Even after contrast delivery, the
Hounsfield unit difference between cancer and normal
pancreatic tissue are nearly identical. Five to 14% of PACs are
often iso-attenuating, blending imperceptibly with the normal
pancreatic parenchyma. Second, is the location of pancreatic
tumors close to exquisitely radiosensitive normal organs at risk
for injury, specifically the small bowel and stomach. Critical is
the fact that the small bowel is a “serial” organ at risk. Meaning if
even a small portion of this organ is injured, the function of the
entire organ is compromised. Clinical consequences of small
bowel injury can be dire. The presence of the small bowel
intimately associated with pancreatic tumors dramatically
limits the ability to deposit meaningful doses of RT. Higher
doses of RT have been associated with improvements in both OS
and local control (22, 23). Yet, this must be done with exquisite
caution for the small bowel in close proximity. Third, is the
presence of highly variable, and unpredictable movement of both
the primary pancreatic tumors and the adjacent normal organs.
This trifecta is difficult to overcome, even with novel strategies
using heavy ions, which are also susceptible to the unique
challenges presented by PACs (24). Each of these components
aggregate to make delivery of curative doses of RT to PACs
exceedingly difficult to accomplish. Beyond just the total dose of
RT, another currently controversial and challenging area is the
optimal treatment volume that should be included. While
historic strategies with SBRT included tumor only, there are
recently published patterns of recurrence data that suggest the
possibility of higher local and regional recurrences around the
vasculature associated with focal SBRT including only the tumor
(25, 26). Local recurrence along vascular structures, secondary to
nearly ubiquitous peri-neural and peri-vascular invasion in PAC,
remains a major concern. Historically, treatment volumes with
fractionated RT have almost uniformly treated regional vascular
structures to reduce this recurrence event. The high rates of
regional nodal failure, secondary to peri-neural and peri-vascular
spread, should be closely considered by radiation oncologists.
MR-Guided Radiation Therapy
MR-guided RT is a novel treatment technique that has emerged
in the past 5 years and presents promise for a variety of solid
tumors. There are two commercially available MRI Linear
accelerators (MR-linac) systems including one by ViewRay
(ViewRay Inc., Oakwood Village, Ohio) and a second by
Elekta (Elekta AB, Stockholm, Sweden) (5). Several review
articles have been published on this topic and a detailed
overview of MR-guidance is beyond the scope of this article
(27–29). In brief, rather than using a CT unit installed within a
linear accelerator to localize the position of a tumor and normal
organs prior to treatment delivery, a MR-linac combines an MRI
device with a linear accelerator. Such a combination enables
several capabilities that are uniquely helpful for the treatment of
PAC. First, MR-guidance offers improved soft tissue contrast and
thereby the ability to distinguish the boundaries of different types
of soft tissue. This can include the location of a tumor, small
bowel, stomach or vascular structures. Second, is that MR
imaging on both commercially available MR linear accelerator
devices is enabled when the beam is turned on and actually
delivering RT. This results in the ability for normal organ
movement to be tracked and monitored during the actual
time of RT delivery. Such “real time” organ movement enables
intra-treatment monitoring and will ultimately enable advanced
dose tracking strategies. In other words, the precise radiation
doses that were actually given to tumor and the normal
structures will be understood during the actual treatment
delivery. Real time imaging will enable entirely novel tracking
approaches, previously unappreciated. Third, with MRgRT at
each fraction a new treatment plan can be generated based
on the actual MRI visualized anatomy. This is especially
important for targets in areas were a large interfraction
variation is expected like in PAC. Finally, in addition to
anatomical imaging, functional and biological MR imaging
can be routinely acquired, the meaning of which remains to be
defined in most solid tumors. However, there is robust literature
in the diagnostic space that many solid tumors exhibit early and
clinically meaningful changes on MRI during a course of either
chemotherapy or RT (30).
Rationale for MR-Guidance In PAC Over
CT-Based Image Guidance
MR-guided therapy has recently presented itself as a highly
appealing new option for patients with PAC. MR-guidance
directly addresses several of the pivotal issues that have existed
for decades with CT-based image guidance. First, is the ability to
distinguish a tumor from normal pancreatic tissue. An example
of a pancreatic tumor on CT simulation is seen in Figure 1A,
despite a contrast enhanced CT, the ability to accurately identify
the edges of many pancreatic tumors is nearly impossible. This is
modestly improved with the use of a 1.5 Tesla MR-linac, even
without IV contrast, as seen on the MR-linac image in Figure 1B.
Additional work is needed to highlight the locations and
conspicuity of pancreatic tumors. Highlighted in Figure 2 is
that many pancreatic tumors are located in such a position that
the movement of small bowel can dramatically impact the dose
of RT to those organs. An example of this is seen in the shaded
region between Figure 2. The presence of bowel in this area
changed significantly between fractions, and dosimetrically the
recorded versus the observed bowel doses were significantly
different. There is almost no question this normal organ
movement has dramatically impacted RT dose in a variety of
tumor sites, and especially in PAC.
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Existing Series That Have Treated PAC
Using MR Guidance
Despite MR-guidance being a relatively novel technological
treatment strategy, there are several published retrospective
series that have examined the ability of MR-guidance to
improve the treatment of PAC. The majority of these
published series have used the ViewRay MR-guided linear
accelerator system (5), primarily because this has been FDA
approved for a longer period of time than the Elekta MR-linac,
and consequently accumulated more clinical data. Most of the
currently published data is early feasibility work or small
retrospective assessments.
One of the earliest clinical experiences examining the use of
MR-guidance for the treatment of PAC was published in 2017.
Bohoudi et al. describe stereotactic MR-guided adaptive
radiation therapy, “SMART”, for the treatment of PAC. In this
study, the gross tumor was contoured and a 3 mm planning
target volume (PTV) margin was applied. A total dose of 40 Gy
in 5 fractions was prescribed, allowing 1% of the PTV to go to
50 Gy (9). This series also presented the feasibility of physicians
adjusting the contours of the organs at risk (OAR’s) within 3 cm
of the PTV, rather than the entire abdominal cavity. Shortly after
this publication, Henke et al. published their experience treating
abdominal tumors that included a total of 3 patients with
FIGURE 1 | CT simulation and fat suppressed T2/T1 MR images acquired from a 1.5 Tesla MR Linear Accelerator. (A) CT Simulation with contrast highlighting
difficult to visualize pancreatic body primary tumor. (B) Slight improvement in visualization with images from 1.5 Tesla MRL, yet still difficult.
FIGURE 2 | Fat suppressed T2/T1 images acquired on a 1.5 Tesla MR Linac with illustration of a tumor in a close proximity to a potential space that can be
occupied by moving small bowel. a. Small biopsy proven pancreatic body tumor. b. Potential space for small bowel to move. c. Example of small bowel movement
in close proximity to gross tumor, max dose went from 26 Gy to 35 Gy (red 35 Gy).
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recurrent PAC, along with 2 patients with primary PAC (10). This
series also included patients treated for other abdominal tumors
such as intra-hepatic cholangiocarcinoma, primary hepatocellular
carcinoma, as well as metastatic disease. Conclusions from this
series were that treatment with MR-guided RT was safe with low
rates of toxicity. A relatively small number of patients with PAC,
however, were represented in this series.
There have been three series published in the past two years
including 25 patients or greater that have retrospectively assessed
local control, toxicity, and OS associated with MR-guided RT in
PAC (11, 12, 14). These series start to provide a window into
clinical outcomes in patients with PAC treated with MR-guided
RT. Important to consider is that MR-guidance is a highly novel
treatment strategy, using unique and complex technology.
Similar to many other complex oncologic interventions (such
as robotic surgery) optimal outcomes will take time to emerge as
techniques, methods, and skill sets using this technology develop
and expand. While learning curves are well documented for
some novel surgical techniques, they remain poorly studied and
understood in advanced RT delivery (9, 31).
In the first of these series, Rudra et al. presented the results of
44 patients treated for inoperable PAC. This was a multi-
institutional series that was one of the earliest to have
aggregated data and presented outcomes focused specifically on
high dose RT given with MR-guidance in PAC. Interestingly, OS
was improved with the use of high dose (a BED10 dose greater
than 70 Gy) MR-guided radiation in this series, 49% versus 30%,
p = 0.03, with impressive rates of local control (over 75%) without
any grade 3 toxicity. Given the retrospective nature of this series,
there is the significant possibility of selection bias that must be
considered when interpreting this data (11). Hassanzadeh et al.
recently published their single institutional data examining
patients treated with high dose ablative radiation for PAC (14).
Again, high rates of local control, over 80%, with very acceptable
rates of GI toxicity were demonstrated. Median OS rates in the
series remained relatively similar at 15.7 months, which is similar
to non-ablative, conventionally fractionated series from multi-
institutional prospective trials. Significant work remains to
understand how improved patient selection can contribute to
improvements in OS.
Finally, Chuong et al. recently published a retrospective
analysis of 35 patients treated using the ViewRay technology
(12). They demonstrate excellent rates of local control and low
reported rates of toxicity. Again, despite these seemingly strong
outcomes, median OS and PFS were relatively similar, compared
with other SABR pancreatic series. Important to note is the time
point from which follow up data is being measured (from the end
of RT versus time of diagnosis). Table 1 summarizes the existing
clinical series to have examined the treatment of PAC using
MR-guidance.
ONGOING PROSPECTIVE TRIALS
Prospective research is desperately needed to examine novel RT
applications in PAC. While retrospective series provide some
framework, they should only be used as tools to design optimal
prospective trials. Patient selection, and the potential for bias in
retrospective studies is a confounder that can simply never be
overcome. There are several ongoing trials that specifically focus
on MR-guidance in PAC. The SMART trial is a well-known
phase II trial examining the use of MR-guided radiation for
locally advanced PAC and is currently accruing (NCT03621644).
A total of 133 patients are planned for enrollment into this multi-
institutional trial. The primary endpoint of this study is grade 3
or higher GI toxicity within 90 days of completion of RT. Given
the relatively modest improvements in outcome over CT-based
image guidance associated with MR-guided RT thus far, the
SMART trial will ideally set the stage for future randomized trials
providing a robust comparison between both CT and MR-
guidance based RT modalities. An example of a patient treated
on this clinical trial can be seen in Figure 3.
A second currently on-going study at Dana Farber Cancer
Institute is a phase I/II study involving patients with either PAC,
lung cancer, or renal cancer (NCT04115254). Primary endpoint
for the phase I portion of the study is delivery success rate for
SMART across multiple tumor types.
Finally the MOMENTUM study (NCT04075305) is an
ongoing prospective registry that is currently collecting
outcomes for patients treated with multiple solid tumors,
including PAC using 1.5 Tesla MR-guidance. In this multi-
institutional study, consisting of 7 centers with Elekta Unity
linear accelerators, patients are being prospectively enrolled and
followed for a multitude of outcomes. Patient-reported quality of
life along with other detailed clinical outcomes data is being
collected, including local recurrence and toxicity events. This will
subsequently be used to inform prospective trials comparing
MR-guided radiation with CT- based radiation.
CURRENT LOGISTICAL APPROACHES TO
ONLINE ADAPTIVE MR BASED
IMAGE GUIDANCE
A detailed discussion of methods, contouring strategies, and
consensus approaches for implementation of online adaptive MR
guidance for PAC is beyond the scope of this article. There are
some helpful publications on PAC in general (32), not
specific to MR-guidance (32). It should be recognized that
online adaptive MR-guidance is a highly complex procedure
that requires an engaged multi-disciplinary team including
radiologists, radiation oncologists, physicists, therapists, and
scheduling coordinators. The details of pancreatic tumor
dosing and MR image guidance implementation has been the
subject of recent publications. Specifically, tumor and normal
organ delineation for PAC using MRI has been addressed in two
recent review articles (33, 34). Dosing strategies, particularly
those that may accomplish ablative dosing, have also been the
subject of several recent review articles (35–37). Ablative dosing
likely offers a higher probability of local control, and its
implementation may be facilitated with online adaptive MR-
guidance; but this remains to be conclusively determined. In
Hall et al. MR Guidance for Pancreatic Adenocarcinoma
Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6281556
addition, device specific methods of online adaption that could
also be considered have also been published (29). Finally, more
practical methods for logistical delivery have been the subject of
other recent publications and maybe of use for centers
considering implementation of online adaptive MR guidance
(13). Each of the clinical outcomes series presented in Table 1
have associated methods that can be referenced for consideration
regarding specific details of treatment strategies that have been
FIGURE 3 | View Ray 0.35 Tesla T2/T1 MR Guided RT. “SMART” patient (NCT03621644) – 50 Gy isodose in red, 33 Gy in cyan. Stomach in yellow, duodenum in
orange, small bowel in green, kidney in blue (courtesy of Dr. Parag Parikh).
FIGURE 4 | Fat suppressed T1 image acquired on a 1.5 Tesla MR Linac immediately after treatment delivery highlighting normal organ movement during treatment
that reflects uncertain dosimetric consequences. a. Movement of small bowel during treatment, differing from adapted contours (green, yellow). b. Void of small
bowel that opened during treatment, actual RT dose to small bowel is likely not accurately measured, despite daily adaption. c. Isodose lines highlighting prescription
dose with fall off.
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applied. In addition, institutional selection criteria as to how
patients are chosen for MR guidance methods in the upper
abdomen have been previously published (13). In general,
collaboration with experts, multi-disciplinary teams, and
enrollment into clinical trials (with clear treatment protocols)
is an optimal strategy for MR-guided treatment. At this time, the
optimal strategy for MR guidance in PAC is still being
determined, and clinical trials with detailed methodology is the
best strategy for that determination.
FUTURE DIRECTIONS
The future of RT in PAC is at a critical precipice. Technology is
rapidly evolving that will improve capabilities with RT. However,
our understanding of how this technology should be optimally
applied in PAC is contingent on prospective trial enrollment and
detailed clinical outcomes publications. Traditional RT concepts,
such as planning risk volumes (PRV’s) accounting for normal
organ movement or appropriate PTV expansions, are
occasionally questioned for patients being treated with real
time MR-guidance. Figure 4 presents an example of how,
despite optimal contour adaption before treatment, normal
structures moved during treatment, and the dosimetric
consequences of this movement are difficult to quantify and
are poorly understood with current technology. Such movement
may continue to justify including a PRV and PTV, unless it can
be corrected or accounted for with exquisite accuracy in real-
time. In theory, real-time treatment plan adaptation as the RT
beam is delivering radiation dose could overcome this issue,
however the computational time requirement associated with
plan re-calculation times and imaging acquisition are currently
prohibitive. That being said, it is only a matter of time before this
computational power and ability is an immediate reality. This
will very likely dramatically shorten treatment times and
improve plan quality. There are many additional areas ripe for
improvement in the therapeutic ratio in PAC. These include
biological imaging-based response assessment (30), artificial
intelligence-enabled real time contour adaptation (38), along
with novel methods to account for accumulated RT dose to
critical local normal structures. The future of highly personalized
and adaptive RT in PAC is exceedingly promising, and radiation
oncologists must lead the way via the education of our surgical
and medical oncology colleagues. Novel RT treatment strategies
need to be considered. Radiation oncologists must work closely
with therapists, and physicists to optimize RT delivery and
conduct ground-breaking clinical research. The systematic
publication of outcomes is absolutely critical. Finally,
randomized trials comparing MR-guidance to CT guidance
would be helpful to quantify the magnitude of any benefit.
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